TrialSignal
Clinical trial intelligence report
A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04709458
Status
UNKNOWN
Phase
Phase 1
Sponsor
Taiga Biotechnologies, Inc.
Executive brief
Investment-Ready Snapshot
Taiga Biotechnologies, Inc. is advancing TBX-2400 through a Phase 1 clinical trial aimed at improving outcomes for patients undergoing allogeneic stem cell transplantation for Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF). The potential to shorten the time to immune reconstitution could position TBX-2400 favorably in a market characterized by high unmet needs in hematologic malignancies. The competitive landscape includes established therapies and emerging candidates targeting similar patient populations. Successful trial outcomes could enhance Taiga's market position and attract partnerships or acquisition interest, given the growing focus on innovative therapies in oncology.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04709458
Indication
Myelofibrosis
Modality
protein therapy
Target
TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.
Intervention
TBX-2400
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.